KR102427527B1 - Fgf21 유도체 및 그것의 용도 - Google Patents

Fgf21 유도체 및 그것의 용도 Download PDF

Info

Publication number
KR102427527B1
KR102427527B1 KR1020177017682A KR20177017682A KR102427527B1 KR 102427527 B1 KR102427527 B1 KR 102427527B1 KR 1020177017682 A KR1020177017682 A KR 1020177017682A KR 20177017682 A KR20177017682 A KR 20177017682A KR 102427527 B1 KR102427527 B1 KR 102427527B1
Authority
KR
South Korea
Prior art keywords
ethoxy
amino
fgf21
oxo
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177017682A
Other languages
English (en)
Korean (ko)
Other versions
KR20170095256A (ko
Inventor
비르지트 비초렉
티나 묄러 타그모세
크리스티안 사스-외룸
비르지테 안데르센
외르겐 올센
Original Assignee
노보 노르디스크 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노보 노르디스크 에이/에스 filed Critical 노보 노르디스크 에이/에스
Publication of KR20170095256A publication Critical patent/KR20170095256A/ko
Application granted granted Critical
Publication of KR102427527B1 publication Critical patent/KR102427527B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020177017682A 2014-12-23 2015-12-22 Fgf21 유도체 및 그것의 용도 Active KR102427527B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14199935 2014-12-23
EP14199935.9 2014-12-23
PCT/EP2015/080969 WO2016102562A1 (en) 2014-12-23 2015-12-22 Fgf21 derivatives and uses thereof

Publications (2)

Publication Number Publication Date
KR20170095256A KR20170095256A (ko) 2017-08-22
KR102427527B1 true KR102427527B1 (ko) 2022-08-01

Family

ID=52130150

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177017682A Active KR102427527B1 (ko) 2014-12-23 2015-12-22 Fgf21 유도체 및 그것의 용도

Country Status (24)

Country Link
US (3) US9744213B2 (https=)
EP (1) EP3236991B1 (https=)
JP (1) JP6727210B2 (https=)
KR (1) KR102427527B1 (https=)
CN (1) CN107108709B (https=)
AR (1) AR103246A1 (https=)
AU (1) AU2015371056B2 (https=)
DK (1) DK3236991T3 (https=)
ES (1) ES2742503T3 (https=)
HK (1) HK1246156B (https=)
HR (1) HRP20191292T1 (https=)
HU (1) HUE044783T2 (https=)
IL (1) IL252438B (https=)
MX (1) MX377044B (https=)
MY (1) MY181181A (https=)
PL (1) PL3236991T3 (https=)
PT (1) PT3236991T (https=)
RS (1) RS59154B1 (https=)
RU (1) RU2729011C2 (https=)
SA (1) SA517381673B1 (https=)
SI (1) SI3236991T1 (https=)
TW (2) TWI708781B (https=)
WO (1) WO2016102562A1 (https=)
ZA (1) ZA201703768B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109414471A (zh) 2016-05-24 2019-03-01 诺和诺德股份有限公司 Mic-1化合物及其用途
CN106421753A (zh) * 2016-10-19 2017-02-22 哈尔滨医科大学 重组人成纤维细胞生长因子‑21在制备预防和治疗缺血性心律失常药物中的应用
TWI710377B (zh) * 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
JP6852939B2 (ja) * 2017-09-04 2021-03-31 ８９バイオ リミテッド８９Ｂｉｏ Ｌｔｄ． 変異体ｆｇｆ−２１ペプチドコンジュゲート及びその使用
CA3104686A1 (en) 2018-07-03 2020-01-09 Bristol-Myers Squibb Company Fgf-21 formulations
US11427623B1 (en) 2019-05-28 2022-08-30 89Bio Ltd. Methods of treatment using mutant FGF-21 peptide conjugates
CN115322794B (zh) 2020-01-11 2025-09-19 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
EP4337680A1 (en) 2021-05-11 2024-03-20 Cytoki Pharma ApS Therapeutic derivatives of interleukin-22
EP4089108A1 (en) 2021-05-11 2022-11-16 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
KR102631925B1 (ko) * 2021-06-10 2024-02-01 토드제약 주식회사 신규 fgf21 변이체 개발 및 이의 생산기법과 용도
CA3224743A1 (en) 2021-07-14 2023-01-19 Beijing Ql Biopharmaceutical Co., Ltd. Fusion polypeptides for metabolic disorders
US20240376168A1 (en) * 2021-09-08 2024-11-14 Leto Laboratories Co., Ltd Fgf21 mutant protein and use thereof
AR129879A1 (es) * 2022-07-08 2024-10-09 Novo Nordisk As Compuestos de isvd altamente potentes capaces de sustituir al fviii(a)
MA71385A (fr) 2022-07-08 2025-04-30 Novo Nordisk A/S Composés isvd hautement puissants capables de remplacer fviii(a)
PE20252745A1 (es) 2023-03-30 2025-12-05 Novo Nordisk As Compuestos de fusion y usos de estos
AR132645A1 (es) * 2023-05-12 2025-07-16 Novo Nordisk As Antagonista de acción prolongada del receptor de la hormona del crecimiento y uso del mismo
TW202511291A (zh) 2023-09-11 2025-03-16 丹麥商諾佛 儂迪克股份有限公司 抗ｉｌ－６結構域之抗體
CN118307684B (zh) * 2024-06-11 2024-10-18 北京志道生物科技有限公司 一种经脂肪酸链修饰的glp-1-fgf21融合蛋白及其制备方法和应用
WO2026012311A1 (zh) * 2024-07-08 2026-01-15 浙江道尔生物科技有限公司 Fgf21衍生物及其用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070237768A1 (en) 2004-05-13 2007-10-11 Eli Lilly And Company Fgf-21 Fusion Proteins
JP2007535306A (ja) 2003-12-10 2007-12-06 イーライ リリー アンド カンパニー 線維芽細胞成長因子２１の突然変異タンパク質
JP2008507477A (ja) 2004-07-08 2008-03-13 ノボ　ノルディスク　アクティーゼルスカブ ポリペプチド延長タグ
WO2010084169A2 (en) 2009-01-23 2010-07-29 Novo Nordisk A/S Fgf21 derivatives with albumin binder a-b-c-d-e- and their use
WO2011154349A2 (en) 2010-06-08 2011-12-15 Novo Nordisk A/S Fgf21 analogues and derivatives
WO2012010553A1 (en) 2010-07-20 2012-01-26 Novo Nordisk A/S N-terminal modified fgf21 compounds
US20120035099A1 (en) 2009-06-11 2012-02-09 Novo Nordisk A/S Fgf21 analogues and derivatives
US20130252884A1 (en) 2009-06-11 2013-09-26 Novo Nordisk A/S Fgf21 analogues and derivatives

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
WO2003011213A2 (en) 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity
EP1329227A1 (en) 2002-01-22 2003-07-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Diagnostic conjugate useful for intercellular imaging and for differentiating between tumor- and non-tumor cells
MXPA05013565A (es) 2003-06-12 2006-03-09 Lilly Co Eli Proteinas de fusion analogas al glp-1.
JP2007537981A (ja) 2003-09-19 2007-12-27 ノボ　ノルディスク　アクティーゼルスカブ 新規の血漿タンパク質親和性タグ
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
JP2007537142A (ja) 2003-12-18 2007-12-20 ノボ　ノルディスク　アクティーゼルスカブ アルブミン様物質に結合した新規のｇｌｐ−１類似物
CA2557782A1 (en) 2004-03-17 2005-10-06 Eli Lilly And Company Glycol linked fgf-21 compounds
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
EA011390B1 (ru) 2004-09-02 2009-02-27 Эли Лилли Энд Компани Мутантные белки (мутеины) фактора роста фибробластов 21
WO2006028714A1 (en) 2004-09-02 2006-03-16 Eli Lilly And Company Muteins of fibroblast growth factor 21
US20080176790A1 (en) 2004-10-29 2008-07-24 Defrees Shawn Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
US7655627B2 (en) 2004-12-14 2010-02-02 Eli Lilly And Company Muteins of fibroblast growth factor 21
WO2006078463A2 (en) 2005-01-21 2006-07-27 Eli Lilly And Company Method for treating cardiovascular disease
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
WO2008087190A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Use of peptides in combination with surgical intervention for the treatment of obesity
CA2682147C (en) 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
CN101663046B (zh) 2007-03-30 2017-07-28 Ambrx公司 经修饰fgf‑21多肽和其用途
CA2693504A1 (en) 2007-08-03 2009-02-12 Eli Lilly And Company Treatment for obesity
US20100261637A1 (en) 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
CN100587073C (zh) 2008-03-24 2010-02-03 吉林农大生物反应器工程有限公司 人成纤维细胞生长因子-21的重组表达
EP2296690B1 (en) * 2008-06-04 2016-11-30 Amgen, Inc Fgf21 mutants and uses thereof
JP5878757B2 (ja) * 2008-10-10 2016-03-08 アムジエン・インコーポレーテツド Ｆｇｆ２１変異体およびその使用
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
EP2427207B1 (en) * 2009-05-05 2017-08-16 Amgen, Inc Fgf21 mutants and uses thereof
HRP20240135T1 (hr) 2009-05-05 2024-04-12 Amgen Inc. Fgf21 mutanti i njihove upotrebe
MX2014002260A (es) * 2011-08-31 2014-08-18 Amgen Inc Factor de crecimiento de fibroblasto 21 para usar en el tratamiento de diabetes tipo 1.
WO2014037373A1 (en) * 2012-09-07 2014-03-13 Sanofi Fusion proteins for treating a metabolic syndrome
MX383664B (es) * 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007535306A (ja) 2003-12-10 2007-12-06 イーライ リリー アンド カンパニー 線維芽細胞成長因子２１の突然変異タンパク質
US20070237768A1 (en) 2004-05-13 2007-10-11 Eli Lilly And Company Fgf-21 Fusion Proteins
JP2008507477A (ja) 2004-07-08 2008-03-13 ノボ　ノルディスク　アクティーゼルスカブ ポリペプチド延長タグ
WO2010084169A2 (en) 2009-01-23 2010-07-29 Novo Nordisk A/S Fgf21 derivatives with albumin binder a-b-c-d-e- and their use
US20100216715A1 (en) 2009-01-23 2010-08-26 Novo Nordisk A/S FGF21 Derivatives With Albumin Binder A-B-C-D-E- And Their Use
US20120035099A1 (en) 2009-06-11 2012-02-09 Novo Nordisk A/S Fgf21 analogues and derivatives
US20130252884A1 (en) 2009-06-11 2013-09-26 Novo Nordisk A/S Fgf21 analogues and derivatives
WO2011154349A2 (en) 2010-06-08 2011-12-15 Novo Nordisk A/S Fgf21 analogues and derivatives
WO2012010553A1 (en) 2010-07-20 2012-01-26 Novo Nordisk A/S N-terminal modified fgf21 compounds

Also Published As

Publication number Publication date
SA517381673B1 (ar) 2020-10-29
IL252438B (en) 2021-09-30
IL252438A0 (en) 2017-07-31
US9895417B2 (en) 2018-02-20
TW202012431A (zh) 2020-04-01
RS59154B1 (sr) 2019-10-31
MX2017007458A (es) 2017-08-10
AR103246A1 (es) 2017-04-26
BR112017011552A2 (pt) 2018-02-14
TWI708781B (zh) 2020-11-01
WO2016102562A1 (en) 2016-06-30
JP6727210B2 (ja) 2020-07-22
TWI681966B (zh) 2020-01-11
MX377044B (es) 2025-03-07
TW201632545A (zh) 2016-09-16
KR20170095256A (ko) 2017-08-22
EP3236991A1 (en) 2017-11-01
CA2972128A1 (en) 2016-06-30
JP2018505146A (ja) 2018-02-22
EP3236991B1 (en) 2019-06-19
AU2015371056A1 (en) 2017-06-15
DK3236991T3 (da) 2019-08-26
PL3236991T3 (pl) 2019-12-31
RU2729011C2 (ru) 2020-08-03
AU2015371056B2 (en) 2020-06-25
US20170182124A1 (en) 2017-06-29
RU2017125050A (ru) 2019-01-25
HUE044783T2 (hu) 2019-11-28
US20170354713A1 (en) 2017-12-14
CN107108709A (zh) 2017-08-29
US9744213B2 (en) 2017-08-29
ZA201703768B (en) 2020-05-27
US10124039B2 (en) 2018-11-13
ES2742503T3 (es) 2020-02-14
RU2017125050A3 (https=) 2019-06-06
SI3236991T1 (sl) 2019-09-30
PT3236991T (pt) 2019-09-06
HRP20191292T1 (hr) 2019-10-18
US20180140673A1 (en) 2018-05-24
CN107108709B (zh) 2021-12-14
HK1246156B (en) 2020-03-27
MY181181A (en) 2020-12-21

Similar Documents

Publication Publication Date Title
KR102427527B1 (ko) Fgf21 유도체 및 그것의 용도
HK1246156A1 (en) Fgf21 derivatives and uses thereof
ES2692495T3 (es) Derivados del FGF21 con aglutinante de albúmina A-B-C-D-E- y sus usos
KR101813595B1 (ko) 장기적 생체 내 효능을 갖는 성장 호르몬
JP6069198B2 (ja) Ｎ末端が修飾されたｆｇｆ２１化合物
US20120172298A1 (en) Glp-1 and fgf21 combinations for treatment of diabetes type 2
JP2013533227A (ja) Ｆｇｆ２１類似体および誘導体
BRPI0607248A2 (pt) conjugado de um polipeptìdeo e um oligossacarìdeo, composição farmacêutica, uso do conjugado, e, processo para a preparação de um conjugado
WO2017220706A1 (en) Pharmaceutical compositions of fgf21 derivatives and uses thereof
US20120035099A1 (en) Fgf21 analogues and derivatives
CA2972128C (en) Fgf21 derivatives and uses thereof
BR112017011552B1 (pt) Derivados de uma proteína do fgf21 e uso terapêutico e/ou profilático dos mesmos
EP2579889A2 (en) Fgf21 analogues and derivatives

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170627

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201215

Comment text: Request for Examination of Application

A302 Request for accelerated examination
PA0302 Request for accelerated examination

Patent event date: 20211026

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220119

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220609

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220727

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220728

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20250630

Start annual number: 4

End annual number: 4